Shire completed acquisition of Dyax Corp. for $37.30/share cash, ~$5.9B total. Adds Phase 3 anti-kallikrein antibody DX-2930 (later lanadelumab/Takhzyro) for HAE prophylaxis to Shire's rare-disease portfolio, complementing FIRAZYR and CINRYZE. Up to $646M contingent value rights tied to FDA approval. Originally announced November 2015.